ARCHIVES

Congressional subcommittee criticizes NIH for lax conflict of interest policies. NIH Director Zerhouni promises change. The subcommittee has asked several NCI officials to testify at another hearing next week.

This article is from The Cancer Letter archive.

Vol. 30 No. 20 | May 14, 2004

Download PDF Visit The Full Archive

Related Articles

ACS Supports NCI’s Bypass Budget In Resolution

March 20, 1992

“With resources now constrained, the ability of NCI to be responsive to its constituencies has been compromised.”

July 7, 1995

FDA orders “limited distribution” for lung cancer drug Iressa.

June 24, 2005

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

December 25, 2009

White House Backs Down FY 86 Cuts, Says Now They Will Be Limited To Trimming Indirect Costs

January 10, 1986

As Avastin Decision Nears, Patient Groups Split On PFS In Front Line Breast Cancer.

February 22, 2008